Fulcrum Therapeutics, Inc. (FULC): restructuring charge — Fulcrum Therapeutics reduces workforce from 80 to 51, expects $10M annual savings

Fulcrum Therapeutics, Inc.

Workforce reduction of 29 employees (36%) to focus on pociredir, DBA, and early discovery; suspends losmapimod.
One-time severance costs of approximately $2 million expected in Q3 2024.
Annual operating expense savings of about $10 million anticipated starting Q1 2025.
Majority of costs incurred by September 30, 2024; implementation substantially complete by Q3 end.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Fulcrum Therapeutics, Inc. announced a restructuring with charges of approximately $2.0 million affecting Company (reduction of the Company's workforce from 80 to 51 full-time employees).

Type: restructuring
Charge: approximately $2.0 million
Affected area: Company
Headcount: reduction of the Company's workforce from 80 to 51 full-time employees

Exact text from the filing

On September 24, 2024, Fulcrum announced the approval by its board of directors of a plan to reprioritize research and development activities to focus on advancing pociredir for the treatment of sickle cell disease, novel therapeutic agents for the treatment of Diamond-Blackfan anemia, and its early discovery programs. The plan will reduce the Company's workforce from 80 to 51 full-time employees, including a reduction of positions across both research and development and general and administrative. Fulcrum expects to incur one-time costs of approximately $2.0 million in connection with this workforce reduction, primarily related to cash payments for severance.

View on SEC.gov

Browse all restructurings & charges →

Fulcrum Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-109069

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.